The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Repurposing Allergy Meds to Treat Hep C

Back to News Homepage

Next

Lyme Disease’s Scary Connection with Hepatitis

Merck’s Chances Are Good for an FDA Approval

June 3, 2015

Print this page

Find out about Merck’s hepatitis drug that is also being tested for HCV/HIV co-infection, liver cirrhosis and more in a clinical trial program.
Merck's Chances Are Good for an FDA Approval

Merck submits NDA for new 2-in-1 hepatitis C treatment

By Nicole Gray

Dive Brief:

  • The FDA will review grazoprevir/elbagavir (100mg/50mg), an investigational single tablet regimen (STR), for treatment of hepatitis C (HCV) genotypes 1, 4 and 6.
  • Previously the FDA granted breakthrough status to grazoprevir/elbagavir for treatment of patients with HCV GT1 with end-stage renal disease on hemodialysis, as well as HCV GT4.
  • Merck will submit additional applications in European and other markets by the end of the year.

Continue reading this entire article:
http://www.biopharmadive.com/news/merck-submits-nda-for-new-2-in-1-hepatitis-c-treatment/399932/

1 Comment
Share
Share

Previous

Repurposing Allergy Meds to Treat Hep C

Back to News Homepage

Next

Lyme Disease’s Scary Connection with Hepatitis

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • Toni Tucker

    How can I get in the study program as a canidid